Eduard Sergienko, PhD - Sanford Burnham Prebys

Prior to joining Sanford Burnham Prebys Eduard Sergienko was at Triad Therapeutics Inc., a company pioneering NMR- and enzymology-guided fragment-based drug discovery approaches. Starting in 2001, Eduard served as Enzymology group leader and member of several drug discovery project teams. The work of his group was instrumental in identification, optimization and characterization of a preclinical candidate acquired by Novartis Pharma AG (Switzerland) for advancing into clinical trials.

Eduard has over 20 years of experience in the field of biochemistry, with an emphasis on assay design and mechanistic enzymology. He graduated and received his PhD in Biochemistry from the Lomonosov Moscow University (Russia), where his doctoral thesis focused on the role of posttranslational modifications in the regulation of glycolytic enzymes. He furthered his expertise through training as a post-doctoral fellow at Henry Poincare University, France, and Rutgers University, New Jersey focusing on mechanistic enzymology, enzyme kinetics and assay design and development.

Select Publications

Showing 1 of 1